How much revenue does Aurobindo Pharma make?

Aurobindo Pharma reported 313.78 billion INR in revenue for fiscal year 2025, up 9.3% from 287.05 billion INR in fiscal year 2024. In Q3 2026 revenue was 86.05 billion INR.

Where does Aurobindo Pharma make most of its revenue?

USA: 46% of revenue by region in fiscal year 2025, followed by Europe (29%).

What companies are similar to Aurobindo Pharma?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Zydus Lifesciences Limited (ZYDUSLIFE.NS), Cipla Limited (CIPLA.NS), Mankind Pharma Limited (MANKIND.NS), Lupin Limited (LUPIN.NS).

Aurobindo Pharma Limited (AUROPHARMA.NS) Stock

About Aurobindo Pharma Limited

Aurobindo Pharma Limited, a pharmaceutical company, develops, manufactures, and commercializes generic pharmaceuticals in India, the United States, Europe, and internationally. The company manufactures a range of finished formulation products in various forms, such as oral solids, liquids, injectables for generic pharmaceuticals, branded specialty pharmaceuticals, and active pharmaceutical ingredi...

At a glance

Aurobindo Pharma reported revenue of 313.78 billion INR for fiscal year 2025, up 9.3% from fiscal year 2024, and net income of 34.86 billion INR. In Q3 2026 (the quarter ended December 31, 2025) revenue was 86.05 billion INR, up 9.0% from a year before. USA was its largest region in fiscal year 2025, with 46% of revenue.

Figures from company filings; latest fiscal year ended March 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.